Skip to content

Search

School experience studies

Besides the challenges associated with their teenage years, adolescents with Type 1 Diabetes (T1D) encounter additional challenges of having a chronic condition.

Smooth sailing for Drina thanks to burden-breaking technology

Recent diabetes technology is helping 12-year-old Drina keep on top of her condition and be independent, while significantly easing the disease burden on her family.

Directing immune development to curb sky-rocketing disease

Once upon a time it was infectious diseases like polio, measles or tuberculosis that most worried parents. With these threats now largely under control, parents face a new challenge – sky-rocketing rates of non-infectious diseases such as asthma, allergies and autism.

What life is like living with type 1 diabetes

Every decision a child with type 1 diabetes makes can impact on their blood glucose levels.

The effect of oral insulin on subcutaneous insulin requirements and glycaemia in T1DM

Liz Tim Davis Jones MBBS FRACP PhD MBBS DCH FRACP MD Co-director of Children’s Diabetes Centre Co-head, Diabetes and Obesity Research Co-director of

Using continuous glucose monitoring to detect early dysglycaemia in children participating in the ENDIA study (Sub Protocol)

Aveni Liz Haynes Davis BA (Hons), MBBChir, MA (Cantab), PhD MBBS FRACP PhD Principal Research Fellow Co-director of Children’s Diabetes Centre

The usability and feasibility of a self-compassion chatbot (COMPASS) for youth living with type 1 diabetes

Although it is well established that youth with type 1 Diabetes (T1D) experience high rates of distress, current clinical care is often under-resourced and unable to provide sufficient or timely psychological support. The current study was designed to evaluate the safety, usability and feasibility of 'COMPASS,' a self-compassion chatbot intervention. 

Short-Term Diabetic Retinopathy Status in People with Type 1 Diabetes Commencing Automated Insulin Delivery

Rapid improvements in glucose control may lead to early worsening of diabetic retinopathy (EWDR). There is a need to demonstrate safety in people commencing automated insulin delivery (AID) due to the known efficacy in rapid glycemic improvement. We aimed to investigate short-term DR outcomes in people (aged ≥13 years) with type 1 diabetes after initiation of AID (use ≥6 months).